Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.

Blood - 1 Oct 2003

Ehrhardt Anja, Xu Hui, Dillow Aaron M, Bellinger Dwight A, Nichols Timothy C, Kay Mark A

Abstract excerpt

Many approaches for treating hemophilia via gene transfer have been attempted in large animal models but all have potential drawbacks. Recombinant adenoviral vectors offer high-efficiency transfer of an episomal vector but have been plagued by the cytotoxicity/immunogenicity of early-generation vectors that contain viral genes. In our current study, we have used a nonintegrating helper-dependent (HD) adenoviral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to DNA, Recombinant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Genetic Vectors

Share to Hemophilia B

Share to Thrombocytopenia

Source

Identifiers

PMID: 12805062
DOI: 10.1182/blood-2003-01-0314

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.PMID 12805062Read ↗

Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector.Semantic proximity Read ↗

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.Semantic proximity Read ↗

Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.Semantic proximity Read ↗

Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.Semantic proximity Read ↗

AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of lifeSemantic proximity Read ↗

Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.Semantic proximity Read ↗

Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapySemantic proximity Read ↗

Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII DeficiencySemantic proximity Read ↗

Translational Data from Adeno-Associated Virus-Mediated Gene Therapy of Hemophilia B in DogsSemantic proximity Read ↗

Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.Semantic proximity Read ↗

Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs.Semantic proximity Read ↗

Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia ASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.